Insider · CIK 0001699624
Michael D Witzeman
cfoofficer
Files at CHE (CHEMED CORP). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 10, 2025 | CHE CHEMED CORP | MOption exercise Capital Stock | +8,796 | $445.35 | $3.9M | 13,154 | Mar 11, 2025 |
| Mar 10, 2025 | CHE CHEMED CORP | FTax withholding Capital Stock | -7,494 | $600.92 | $4.5M | 5,660 | Mar 11, 2025 |
| Mar 10, 2025 | CHE CHEMED CORP | MOption exercise Stock Option (right to buy with tandem tax withholding)derivative | -8,796 | $445.35 | $3.9M | 34,484 | Mar 11, 2025 |
| Feb 14, 2025 | CHE CHEMED CORP | MOption exercise Capital Stock | +652 | $553.39 | $361k | 4,436 | Feb 18, 2025 |
| Feb 14, 2025 | CHE CHEMED CORP | MOption exercise Capital Stock | +198 | $553.39 | $110k | 4,634 | Feb 18, 2025 |
| Feb 14, 2025 | CHE CHEMED CORP | FTax withholding Capital Stock | -276 | $553.39 | $153k | 4,358 | Feb 18, 2025 |
| Feb 14, 2025 | CHE CHEMED CORP | MOption exercise Performance Stock Unitsderivative | -323 | $0.00 | $0 | 1,931 | Feb 18, 2025 |
| Feb 14, 2025 | CHE CHEMED CORP | MOption exercise Performance Stock Unitsderivative | -323 | $0.00 | $0 | 1,608 | Feb 18, 2025 |
| Feb 14, 2025 | CHE CHEMED CORP | AGrant or award Performance Stock Unitsderivative | +1,128 | $0.00 | $0 | 2,736 | Feb 18, 2025 |
| Oct 22, 2024 | CHE CHEMED CORP | AGrant or award Stock Option (right to buy with tandem tax withholding)derivative | +13,395 | $597.70 | $8.0M | 43,280 | Oct 23, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.